Main characteristics at diagnosis of the 282 evaluable patients according to treatment group
| . | Arm A TBI + HDM140 (n = 140) . | Arm B HDM 200 (n = 142) . | P . |
|---|---|---|---|
| Age | 60 (36-65) | 61 (42-65) | .16 |
| Male gender | 58 (41) | 65 (46) | .61 |
| Durie-Salmon stage | |||
| I | 10 (7) | 8 (6) | .78 |
| II | 20 (14) | 27 (19) | .37 |
| III | 110 (79) | 107 (75) | .62 |
| M component | |||
| IgG | 80 (57) | 79 (56) | .89 |
| IgA | 36 (26) | 37 (26) | .94 |
| Bence Jones | 24 (17) | 26 (18) | .92 |
| Hemoglobin (g/dL) | 10.9 (5.4-16.8) | 11.1 (5.6-15.2) | .3 |
| Serum calcium (mM) | 2.4 (2-4) | 2.4 (1.9-3.5) | .51 |
| Serum creatinine (μM/L) | 95 (59-395) | 88 (50-306) | .24 |
| Serum β2-microglobulin (mg/L) | 3.1 (1.1-16.2) | 3.2 (1-20) | .46 |
| C-reactive protein (mg/L) | 5 (1.7-200) | 5 (1-75) | .96 |
| . | Arm A TBI + HDM140 (n = 140) . | Arm B HDM 200 (n = 142) . | P . |
|---|---|---|---|
| Age | 60 (36-65) | 61 (42-65) | .16 |
| Male gender | 58 (41) | 65 (46) | .61 |
| Durie-Salmon stage | |||
| I | 10 (7) | 8 (6) | .78 |
| II | 20 (14) | 27 (19) | .37 |
| III | 110 (79) | 107 (75) | .62 |
| M component | |||
| IgG | 80 (57) | 79 (56) | .89 |
| IgA | 36 (26) | 37 (26) | .94 |
| Bence Jones | 24 (17) | 26 (18) | .92 |
| Hemoglobin (g/dL) | 10.9 (5.4-16.8) | 11.1 (5.6-15.2) | .3 |
| Serum calcium (mM) | 2.4 (2-4) | 2.4 (1.9-3.5) | .51 |
| Serum creatinine (μM/L) | 95 (59-395) | 88 (50-306) | .24 |
| Serum β2-microglobulin (mg/L) | 3.1 (1.1-16.2) | 3.2 (1-20) | .46 |
| C-reactive protein (mg/L) | 5 (1.7-200) | 5 (1-75) | .96 |
Median values are given for continuous variables, while the number of patients (%) is given otherwise.